SB-480848 (darapladib)

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Atherosclerosis

Phase 1

Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-

CompletedNCT00622830

GlaxoSmithKlineAtherosclerosis

Start: 2008-01-31End: 2008-03-31Target: 18Updated: 2016-11-03

A Study With Darapladib to Collect Tolerability Information

CompletedNCT00704431

GlaxoSmithKlineAtherosclerosis

Start: 2008-05-31End: 2008-10-31Updated: 2016-11-04